Introduction
Critical limb ischaemia (CLI) is a peripheral arterial disease associated with poor quality of life. CLI is generally treated with endovascular revascularization or surgical bypass, however, 30% of patients are not eligible for such therapies. 1 In these untreatable patients, the amputation rate is $10-40% with an increase predicted in elderly patients and patients with diabetes. Cell therapy has emerged as a promising strategy for the recovery of damaged tissue. Clinical trials for stem cell therapy for CLI appear to have increased the rate of amputation-free survival (AFS). 2 However, randomized placebo-controlled trials show that bone marrow-derived stemcell therapy has not significantly increased AFS. 3 Furthermore, meta-analyses of clinical trials with bone marrow cells have revealed marginal therapeutic effects in heart function. 4 Therefore technological development of stem cell therapy is required to improve the marginal therapeutic effects in ischaemic (cardio)vascular diseases. It has been reported that chemotactic cytokines (chemokines) play a pivotal role in angiogenesis, immunity, and tumorigenesis. [5] [6] [7] Recent reports demonstrate that the overexpression of granulocyte chemotactic protein-2 (GCP-2/CXCL6) results in enhanced angiogenesis. 8 In addition, it has been noted that over-expression of another potent chemokine, stromal-derived factor-1 alpha (SDF-1a/CXCL12) promotes the angiogenic property in MSC. 9 The present study, hypothesized that overexpression of dual chomokines may maximize angiogenic effects in adipose mesenchymal stem cells (ASCs). This study first characterized the angiogenic properties of ASCs overexpressing dual GCP-2 and SDF-1a (ASC-G/S).
Methods

Cell culture
Human umbilical vein endothelial cells (HUVECs) and human dermal fibroblast (HDFs) were purchased from ATCC (Manassas, VA, USA). Human ASCs were purchased from Thermo Scientific Inc. (Rockford, IL, USA). ASCs were cultured in low-glucose Dulbeccco's Modified Eagle Medium (DMEM; Gibco, Grand Island, NY, USA) supplemented with 10% fetal bovine serum (FBS), 100 U/mL penicillin, and 100 lg/mL streptomycin (Gibco). 10, 11 HUVECs were cultured in endothelial growth complete media (EGM-2) (Lonza Walkersville, MD, USA). Human embryonic kidney 293 T (HEK293T; ATCC) cells were cultured in (DMEM) with 10% FBS, 100 U/mL penicillin, and 100 lg/mL streptomycin at 37 C and 5% CO 2 . One batche of HUVECs and ASCs and less than passage 5 HUVECs and ASCs were used for this study.
Construction of expression vectors
The published sequence of human CXCL6 (GCP-2, accession number NM_002993.3) and CXCL12 (SDF-1a, accession number NM_199168.3) were obtained from the GenBank database. The DNA sequence XbaI-CXCL6 (GCP-2)-NheI and XbaI-CXCL6-P2A-CXCL12 (SDF-1a)-BamHI were synthesized by the Bioneer Company (Daejeon) and GCP-2/SDF-1 was linked by a P2A self-cleavage sequence. The lentiviral vector used in this study was pLV-EF1a-MSC-internal ribosomal entry site (IRES)-red fluorescent protein (RFP)-Neo (Biosettia). The GCP-2 gene was cloned as an XbaI-NheI DNA fragment into pLV-EF1a-MSC-IRES-RFP-Neo vector. Similarly, the pLV-GCP2/SDF1a-RFP was constructed by inserting the GCP-2/SDF1a linked by a P2A self-cleavage sequence as XbaI-BamHI to pLV-EF1a-MSC-IRES-RFP-Neo.
Lentiviral vector production and transduction
The 293 T cells were seeded at 6Â10 6 cells in 10 cm 2 plates. After 24 h, the cells were transfected using Lipofectamine 3000 (Invitrogen) with the following plasmids: pMDLg/p RRE (Gag-Pol expression plasmid), pCMV-VSV-G-RSV-Rev (Rev and VSV-G env expression plasmid), and either pLV-EF1-GCP2-IRES-RFP-Neo (GCP-2 expression plasmid) or pLV-EF1-GCP2/SDF-1-IRES-RFP-Neo (GCP-2 and SDF-1a expression plasmid). After 48 h, the lentivirus containing supernatant was collected, and filtered through 0.45 lm filters. The cells were infected with 10 mL of viral supernatants in the presence of 100 lg/mL protamine sulfate (Sigma). At 3-day post-infection, the infected cells were detected by fluorescence microscopy.
Flow cytometry
Cells were suspended in phosphate-buffered saline (PBS) containing 1% BSA and incubated for 20 min with FITC-or phycoerythrin (PE)-conjugated monoclonal antibodies specific for CD29, CD44, CD45, CD73, CD90, and CD105. All antibodies were purchased from BD Pharmingen (San Diego, CA, USA). Proper isotype-identical IgGs were used as controls. Stained cells were analysed with a flow cytometer (Becton Dickinson, San Jose, CA, USA). 
Conditioned media preparation
Cell media (CM) were prepared as described in previous literature.
14 Briefly, 10 6 cells were seeded into T-75 cell culture flasks and grown in normal medium-or low-glucose DMEM(Gibco) containing 10% FBS, 100 U/mL penicillin, and 100 mg/mL streptomycin (Gibco) for 48 h until the cells reached approximately 80% confluence. CM were then centrifuged and the supernatantswere collected and used for this study.
Scratch migration assay
Scratch wound assays were performed by a method established in previous literature modifications. 14 HDFs were seeded to a final density of 10 5 cells/well in 24-well culture plates coated with type I collagen (0.2 mg/mL) and incubated at 37 C in 5% CO 2 for 27 h to produce confluent monolayers. Monolayers were scratched using a sterile pipette tip and incubated with each of the following CM, which had been cultured for 5 days: HDFs, ASC, ASC-G, and ASC-G/S. To measure cell mobility, images were obtained at five random fields after scratching. Wound areas were examined, using the NIH Image program (http://rsb.info.nih. gov/nih-image/).
Matrigel tube formation assay
To planted into the ischaemic hind limb area after surgery (n = 7 for each group). Euthanasia was conducted by intravenous injection of thiopentalsodium (40 mg/kg). The serial blood flow in the hind limb was analysed using laser Doppler perfusion imaging (Moor Instruments, Axminster, UK).
Matrigel plug in vivo assay
Histological analysis
Histological analysis was conducted as described in previous literature. 12 Briefly, the adductor muscles were harvested, fixed in paraformaldehyde for 4 h, and incubated overnight in a 15% sucrose solution. The tissues were embedded in (OCT) compound (Sakura Finetek USA, Torrance, CA, USA) and sectioned into 10-lm-thick sections. Five frozen sections from each group of ischaemic tissues were stained with biotinylated isolectin B4 (ILB4, 1:250; Vector Laboratory Inc., Burlingame, CA, USA) primary antibodies, followed by streptavidin Alexa Fluor 488 (1:400; Invitrogen) secondary antibodies for the capillary density measurement. Next, five fields from five tissue sections were randomly selected, and the number of capillaries was counted.
Quantification of co-localized cells in ischaemic hind limb tissue
Co-localized cells in the ischaemic hind limbs were quantified by histological analyses as described in previous literature. 16 Briefly, cells were injected into the ischaemic hind limbs of mice. After 4 weeks, the ischaemic hind limb tissue sections were embedded and sectioned. Then, five fields from four tissue sections were randomly selected, and the number of cells was counted in each field.
Statistical analysis
All data are presented as mean ± SD. Statistical analyses were conducted using Student's t-test for comparisons of 2 groups, and ANOVA with Bonferroni's multiple comparison test using SPSS v11.0. Data with P < 0.05 were considered statistically significant. Graphs were drawn using GraphPad Prism v7.04.
Results
Cell characteristics
The morphology of the newly constructed ASCs overexpressing single GCP-2 (ASC-G) and ASC-G/S were compared with that of the control ASCs. Both ASC-G and ASC-G/S exhibited a spindle shape and we confirmed >90% has a single or double transgene by fluorescence-activated cell sorting (FACS) analysis ( Figure 1A and B) . In addition, their proliferation rate was similar to that of the control ASCs ( Figure 1C ). To further characterize ASC-G and ASC-G/S, the surface marker expression was examined using FACS analysis. Representative mesenchymal stem cells and hematopoetic cells markers were analysed. Both ASC-G and ASC-G/S exhibited very low levels of hematopoietic cell (CD45) markers and high levels of mesenchymal stem cell (CD29, CD44, CD73, CD90, CD105) markers ( Figure 1D ). These data indicate that ASC-G and ASC-G/S possess the characteristics of normal mesenchymal stem cells.
ASC-G/S exhibit enriched expression of pro-angiogenic and endothelial genes
To test the angiogenic potential of ASC-G/S, pro-angiogenic gene expression was evaluated using qRT-PCR. ASC-G/S was compared with ASC-G and normal ASCs as control cells. It was first confirmed that ASC-G/S exhibited significantly higher levels of GCP-2 and SDF-1a expression compare with ASCs. In addition, ASC-G/S exhibited significantly higher levels of representative pro-angiogenic factors, angiopoietin (Ang)-1, and vascular endothelial growth factor (VEGF)-A compared with ASC-G ( Figure 2A) . Next, to compare the endothelial cells (EC) differentiation potential of ASC-G/S, ASC-G, and normal ASCs, each cells was cultured in EGM-2, which is endothelial cell basal media-2 with cytokine cocktail for 14 days. To examine the EC-specific gene expression, we performed RT-PCR and qRT-PCR. Interestingly, RT-PCR results showed that ASC-G/S highly expressed von Willebrand factor (vWF), Flt-1, Flk-1, and Tie-2 compare with ASC ( Figure 2B ). qRT-PCR results also revealed that ASC-G/S significantly expressed vWF, Flt-1, and Tie-2 compare with ASC ( Figure 2C ).
Secreted factors from ASC-G/S enhance cell migration and matrigel tube formation
To examine whether secreted factors from ASC-G/S promote cell migration, a scratch wound assay was performed. The assay revealed that ASC-G/S derived CM significantly increased the rate of fibroblast migration as compared with that from ASC-G CM and ASC CM at 27 h ( Figure  3A and B) . Figure 3C and D) . These data indicate that the secreted factors derived from ASC-G/S have high angiogenic properties.
ASC-G/S demonstrate vasculogenic potential
To test the in vivo vasculogenic potential, a Matrigel plug assay was conducted. ASC-G/S, ASC-G, and ASC, mixed at a concentration of 5 Â 10 5 with Matrigel 500 lL, were transplanted into nude mice subcutaneously. After 2 weeks, Matrigel plugs were harvested and hemoglobin content was examined. Notably, significantly higher levels of red blood cells, indicating functional vascular formation, were found in the Matrigel plugs containing ASC-G/S than in plugs containing ASC-G and ASC ( Figure 4A and B) . However, red blood cells were not detected in the Matrigel control PBS group. To confirm whether transplanted ASC-G/S differentiated into vasculature in the Matrigel plug, an immunohistochemistry study was performed. Histological data revealed that ASC-G/S formed vasculature-like structures and expressed the endothelium-specific protein, isolectin B4 (ILB4) ( Figure 4C ). 
ASC-G/S demonstrates therapeutic effects on hind limb ischaemia
To investigate the therapeutic effects after cell transplantation, hindlimb ischaemia was induced in nude mice. For this, 1Â 10 6 cells or PBS were intramuscularly injected into the ischaemic hindlimb area after surgery. Laser Doppler perfusion imaging showed that the blood perfusion rate in ASC-G/S injected limbs was significantly higher than that in limbs injected with ASC or ASC-G at day 7 and 14 ( Figure 5A and B) . In addition, and most notably, the ASC-G/S cell-injected mice showed a higher limb-salvage ratio than the ASC-G, ASC, and PBS control groups ( Figure  5C and D).
ASC-G/S enhances capillary density inhindlimb muscle
To elucidate the mechanism underlying the high limb salvage rate and enhanced recovery of blood flow for limbs injected with ASC-G/S, capillary density was measured from the histological experiment using a marker for endothelial cells, ILB4. The number of capillaries was significantly higher in the ASC-G/S-treated mice than in the PBS-treated mice and as compared with the ASC-or ASC-G-treated control mice on day 7 ( Figure 6A and B) . Next, to further elucidate the therapeutic mechanisms underlying the high limb salvage rate, the changes in the angiogenic factors in hind limb tissues were measured, using qRT-PCR analysis. Results revealed that ASC-G/S injected limbs significantly upregulated VEGF-A, hepatocyte growth factor (HGF), epidermal growth factor (EGF), and figrobalst growth factor (FGF)-2 as compared with the ASC-G-or ASC-treated hind limb tissues at 3 days after cell injection. These data indicate that ASC-G/S injection promotes multiple angiogenic biological factors for vascular regeneration in vivo ( Figure 6C) .
Lastly, to evaluate the endothelial differentiation potentials of ASC-G/ S in vivo hind limb muscle tissues were collected 4 weeks after cell transplantation. Immunohistochemistry results demonstrated that some of the ASC-G/S exhibited colocalizing with ILB4, which is an endotheliumspecific marker, forming vascular-like round structure ( Figure 6D ).
Discussion
This study, first demonstrates that dual chemokine genes overexpressing ASC has robust angiogenic and vasculogenic potential, suggesting that strategy is useful for treating ischaemic cardiovascular disease. The major findings are as follows: (i) ASC-G/S was enhanced expression of proangiogenic genes. (ii) Transplantation of ASC-G/S into ischaemic hind limbs results in enhanced recovery of tissue ischaemia. (iii) The implanted ASC-G/S produced a favorable environment for neovascularization.
The roles of chemokines are, first, pro-inflammatory action, recruiting to an infection site during an immune response, and second, a homeostatic role, controlling cell migration as part of tissue regeneration and maintenance. In terms of tissue repair action, chemokines have been reported to play a crucial role in angiogenesis, and it has been suggested that chemokines secreted from stem cells can perform vital paracrine actions. 17 GCP-2, which is chemokine ligand 6 (CXCL6), belongs to the CXC chemokine family, known as a chemoattractant and reported to have angiogenic potential. 7, 18 Recently, it has been demonstrated that (hASCs) overexpressing GCP-2 exhibit the enhanced angiogenic capacity to repair damaged ischaemic tissue. 8 GCP-2 single-factor overexpression triggers other proangiogenic growth factors in ASCs such as VEGF-A, HGF, insulin growth Thus, one may speculate that other potent SDF-1a proteins may synergize the angiogenic function in ASC. SDF-1a, known as CXCL12, activates leukocytes and is induced by proinflammatory response. It also has been noted that SDF-1a overexpressing cardiac stem cells show enhanced migration, engraftment, and reduced infarct size. 19 The current study made a GCP-2/SDF-1a -overexressing ASC cell line via a lenti-viral system. During the cell culture period, ASC-G/S did not show morphologic, cell-growth rate, and surface protein changes were comparable to that of normal, untreated ASCs. However, qRT-PCR results revealed that three angiogenic factors (Ang-1, EGF, and VEGF-A) exhibited enhanced expression levels in ASC-G/S as compared with those of ASC-G. The functional relevance of these angiogenic factors might be related the synergistic effects of those up-regulated genes on the induction of angiogenesis. 20 High expression of SDF-1a stimulate VEGF secretion 21 and VEGF mediated signaling pathways might activate for these angiogenic synersism. 22 In addition, SDF-1a might provide favorable pro-neovascularization environment to promote therapeutic neovascularization. At the same time, angiogenic gene expression of single chemokine-overexpressing ASC-G, IGF-1, HGF, and Il-8 did not display enhanced expression levels in dual chemokine-overexpressing ASC-G/S. These results suggest that autocrine interaction of overexpressing dual chemokines may occur as a homeostatic role to regulate a certain physiological action of cells, displaying down-regulated angiogenic factors. However, more additional evidences regarding signaling cascades or interatctions after SDF-1a/ CXCL6 over-expression should be investigated in futher studies. Recently, the major angiogenic effects of stem cells has been examined through paracrine mechanisms. 23 Since migration and tube formation are essential to angiogenesis, 24 those potentials were evaluated in the present study. In line with the qRT-PCR data, the CM from ASC-G/S highly enhanced the cell migration of fibroblast. In vivo vasculogenesis assays using Matrigel showed that treatment with CM from ASC-G/S resulted in excellent formation of a tube network in vitro. Furthermore, the ASC-G/S Matrigel plugs in mice were filled with red blood cells and showed vessel like structures. High levels of Ang-1 expression from ASC-G/S may stimulate microvessel-like network formation by interacting with another paracrine factor, VEGF-A. 25 In addition, high expression of EGF derived from ASC-G/S may promote angiogenesis or angiogenic synergism in combination with VEGF-A, Ang-1, and IL-8. These data suggest that G/S may create a key modulating to enhance the cell migration angiogenic processes. All the angiogenic potentials of dual chemokine-overexpressing ASC in vitro were re-evaluated in vivo using ischaemic hindlimb mouse model. In line with the in vitro data, ASC-G/S transplantation markedly promoted the recovery of blood perfusion and capillary density in the ischaemic hind limb adductor muscles, resulting in low limb loss and high limb salvage rates. These results indicate that local injection of ASC-G/S may induce angio-vasculogenesis by highly secreted pro-angiogenic factors, (Ang-1, IL-8, and VEGF-A). It was also speculated that chemotactic factors GCP-2 and SDF-1a may play major roles in triggering firm adhesion of monocytes or circulating angiogenic progenitor cells to the vascular endothelium and macrophage mediating angiogenesis. 26, 27 A recent controversy regarding the endothelial (trans)differentiation potential of transplanted stem cells has arisen. [28] [29] [30] [31] It has been reported that SDF-1a significantly induces MSCs into endothelial cells 9 and, recently, it has been demonstrated that GCP-1 overexpressing ASC shows high endothelial differentiation. 8 To evaluate the endothelial differentiation potential of ASC-G/S, the endothelial characteristics were checked. Notably, RT-PCR and qRT-PCR data demonstrated that ASC-G/S expresses a high level of endotheliumspecific genes, EC-specific genes, VEGF receptors 1, 2 (Flt-1 and Flk-1), Tie-2, and vWF, indicating the possibility of endothelial commitment and differentiation. Consistent with these data, immunocytochemistry data revealed that injected ASC-G/S incorporat into a vasculature-like structure, and express the endothelium-specific protein IL-B4. These results indicate that ASC-G/S possesses robust vasculogenic characteristics.
In conclusion, ASC-G/S exhibits high angiogenic and vasculogenic characteristics, indicating that overexpressing dual chemokine G/S may present an alternative strategy to enhance the therapeutic function of stem cells and use for treat ischaemic cardiovascular diseases. However, further investigation by clinical study may be required to test the longterm safety and effectiveness of this approach. 
